Summary Recommendation

The following taxane containing regimens are considered reasonable treatment options for the target population:

• Six cycles of three-weekly docetaxel, doxorubicin, and cyclophosphamide (TAC) (75/50/500mg/m²)
• Four cycles of doxorubicin and cyclophosphamide (AC) (60/600mg/m²) followed by four cycles of paclitaxel (175mg/m² or 225mg/m² every three weeks or 175 mg/m² every two weeks with granulocyte colony-stimulating factor [G-CSF]).
• Three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 followed by three cycles of docetaxel (100 mg/m²)

These regimens are recommended over their non-taxane containing counterparts (six cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC), four cycles of AC, and six cycles of FEC-100), as they have been shown to be superior in efficacy. Taxane-containing counterparts to other commonly used non-taxane anthracycline regimens (e.g., cyclophosphamide, epirubicin, 5-fluorouracil [CEF]) have not yet been evaluated by randomized clinical trials. However, these non-taxane-containing regimens remain reasonable treatment options.